“ If their drug works,and patients walk out of hospital with no further respiratory complications - then suddenly there is no one in further need of critical care and thus our stem cells. “
1. We don’t have trial results yet, so we can’t tell if their drug works, or if these patients were going to recover naturally anyway.
2. Patients can rapidly deteriorate, and it may not be viable to treat many before developing a need for critical care.
3. Even if it does work, it can do nothing for helping to repair any damage to the lungs, so it is premature to assume recovered patients will have no further need of stem cells.
- Forums
- ASX - By Stock
- MSB
- Gilead vs Mesoblast
Gilead vs Mesoblast, page-33
-
- There are more pages in this discussion • 242 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.53 |
Change
0.010(0.66%) |
Mkt cap ! $1.712B |
Open | High | Low | Value | Volume |
$1.50 | $1.54 | $1.48 | $5.605M | 3.713M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 55197 | $1.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.53 | 29782 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2371 | 1.645 |
3 | 5137 | 1.605 |
5 | 24406 | 1.600 |
1 | 926 | 1.585 |
7 | 8180 | 1.565 |
Price($) | Vol. | No. |
---|---|---|
1.445 | 2383 | 2 |
1.450 | 5323 | 1 |
1.475 | 2680 | 1 |
1.480 | 10000 | 1 |
1.490 | 63740 | 1 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online